Shots:

• The P-I THINK ongoing trial is assessing CYAD-01 in mCRC patients administering cyclophosphamide (300 mg/m²) and fludarabine (30 mg/m²)- evaluating its safety and ATR
• CYAD-01 investigational CAR-T therapy with expressing NKG2D receptor of NK cells- administration has shown no toxicity till date in its first enrolled patient in THINK trial  
• CYAD-01 is under clinical stage with number of trials for haematological malignancies and solid tumours

Ref: Celyad | Image: PRNewswire